Summary
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Prenatal Genetic Testing market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Prenatal Genetic Testing market segmented into
Diagnostic Test
Chorionic Villi Sampling (CVS)
Amniocentesis
Placental Biopsy
Cordocentesis
Fetal Biopsy
Screening Test
Carrier Screening
Sequential Screening
Maternal Serum Quad Screening
Based on the end-use, the global Prenatal Genetic Testing market classified into
Hospitals
Clinics
Diagnostic Centers
Based on geography, the global Prenatal Genetic Testing market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
Sequenom Laboratories
Illumina
Natera
Ariosa Diagnostics
BGI Health
Natera
LifeCodexx
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Prenatal Genetic Testing market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Prenatal Genetic Testing market segmented into
Diagnostic Test
Chorionic Villi Sampling (CVS)
Amniocentesis
Placental Biopsy
Cordocentesis
Fetal Biopsy
Screening Test
Carrier Screening
Sequential Screening
Maternal Serum Quad Screening
Based on the end-use, the global Prenatal Genetic Testing market classified into
Hospitals
Clinics
Diagnostic Centers
Based on geography, the global Prenatal Genetic Testing market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
Sequenom Laboratories
Illumina
Natera
Ariosa Diagnostics
BGI Health
Natera
LifeCodexx
Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL PRENATAL GENETIC TESTING INDUSTRY
2.1 Summary about Prenatal Genetic Testing Industry
2.2 Prenatal Genetic Testing Market Trends
2.2.1 Prenatal Genetic Testing Production & Consumption Trends
2.2.2 Prenatal Genetic Testing Demand Structure Trends
2.3 Prenatal Genetic Testing Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Diagnostic Test
4.2.2 Chorionic Villi Sampling (CVS)
4.2.3 Amniocentesis
4.2.4 Placental Biopsy
4.2.5 Cordocentesis
4.2.6 Fetal Biopsy
4.2.7 Screening Test
4.2.8 Carrier Screening
4.2.9 Sequential Screening
4.2.10 Maternal Serum Quad Screening
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hospitals
4.3.2 Clinics
4.3.3 Diagnostic Centers
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Diagnostic Test
5.2.2 Chorionic Villi Sampling (CVS)
5.2.3 Amniocentesis
5.2.4 Placental Biopsy
5.2.5 Cordocentesis
5.2.6 Fetal Biopsy
5.2.7 Screening Test
5.2.8 Carrier Screening
5.2.9 Sequential Screening
5.2.10 Maternal Serum Quad Screening
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hospitals
5.3.2 Clinics
5.3.3 Diagnostic Centers
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Diagnostic Test
6.2.2 Chorionic Villi Sampling (CVS)
6.2.3 Amniocentesis
6.2.4 Placental Biopsy
6.2.5 Cordocentesis
6.2.6 Fetal Biopsy
6.2.7 Screening Test
6.2.8 Carrier Screening
6.2.9 Sequential Screening
6.2.10 Maternal Serum Quad Screening
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hospitals
6.3.2 Clinics
6.3.3 Diagnostic Centers
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Diagnostic Test
7.2.2 Chorionic Villi Sampling (CVS)
7.2.3 Amniocentesis
7.2.4 Placental Biopsy
7.2.5 Cordocentesis
7.2.6 Fetal Biopsy
7.2.7 Screening Test
7.2.8 Carrier Screening
7.2.9 Sequential Screening
7.2.10 Maternal Serum Quad Screening
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hospitals
7.3.2 Clinics
7.3.3 Diagnostic Centers
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Diagnostic Test
8.2.2 Chorionic Villi Sampling (CVS)
8.2.3 Amniocentesis
8.2.4 Placental Biopsy
8.2.5 Cordocentesis
8.2.6 Fetal Biopsy
8.2.7 Screening Test
8.2.8 Carrier Screening
8.2.9 Sequential Screening
8.2.10 Maternal Serum Quad Screening
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hospitals
8.3.2 Clinics
8.3.3 Diagnostic Centers
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Diagnostic Test
9.2.2 Chorionic Villi Sampling (CVS)
9.2.3 Amniocentesis
9.2.4 Placental Biopsy
9.2.5 Cordocentesis
9.2.6 Fetal Biopsy
9.2.7 Screening Test
9.2.8 Carrier Screening
9.2.9 Sequential Screening
9.2.10 Maternal Serum Quad Screening
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hospitals
9.3.2 Clinics
9.3.3 Diagnostic Centers
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Sequenom Laboratories
10.1.2 Illumina
10.1.3 Natera
10.1.4 Ariosa Diagnostics
10.1.5 BGI Health
10.1.6 Natera
10.1.7 LifeCodexx
10.2 Prenatal Genetic Testing Sales Date of Major Players (2017-2020e)
10.2.1 Sequenom Laboratories
10.2.2 Illumina
10.2.3 Natera
10.2.4 Ariosa Diagnostics
10.2.5 BGI Health
10.2.6 Natera
10.2.7 LifeCodexx
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL PRENATAL GENETIC TESTING INDUSTRY
2.1 Summary about Prenatal Genetic Testing Industry
2.2 Prenatal Genetic Testing Market Trends
2.2.1 Prenatal Genetic Testing Production & Consumption Trends
2.2.2 Prenatal Genetic Testing Demand Structure Trends
2.3 Prenatal Genetic Testing Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Diagnostic Test
4.2.2 Chorionic Villi Sampling (CVS)
4.2.3 Amniocentesis
4.2.4 Placental Biopsy
4.2.5 Cordocentesis
4.2.6 Fetal Biopsy
4.2.7 Screening Test
4.2.8 Carrier Screening
4.2.9 Sequential Screening
4.2.10 Maternal Serum Quad Screening
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hospitals
4.3.2 Clinics
4.3.3 Diagnostic Centers
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Diagnostic Test
5.2.2 Chorionic Villi Sampling (CVS)
5.2.3 Amniocentesis
5.2.4 Placental Biopsy
5.2.5 Cordocentesis
5.2.6 Fetal Biopsy
5.2.7 Screening Test
5.2.8 Carrier Screening
5.2.9 Sequential Screening
5.2.10 Maternal Serum Quad Screening
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hospitals
5.3.2 Clinics
5.3.3 Diagnostic Centers
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Diagnostic Test
6.2.2 Chorionic Villi Sampling (CVS)
6.2.3 Amniocentesis
6.2.4 Placental Biopsy
6.2.5 Cordocentesis
6.2.6 Fetal Biopsy
6.2.7 Screening Test
6.2.8 Carrier Screening
6.2.9 Sequential Screening
6.2.10 Maternal Serum Quad Screening
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hospitals
6.3.2 Clinics
6.3.3 Diagnostic Centers
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Diagnostic Test
7.2.2 Chorionic Villi Sampling (CVS)
7.2.3 Amniocentesis
7.2.4 Placental Biopsy
7.2.5 Cordocentesis
7.2.6 Fetal Biopsy
7.2.7 Screening Test
7.2.8 Carrier Screening
7.2.9 Sequential Screening
7.2.10 Maternal Serum Quad Screening
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hospitals
7.3.2 Clinics
7.3.3 Diagnostic Centers
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Diagnostic Test
8.2.2 Chorionic Villi Sampling (CVS)
8.2.3 Amniocentesis
8.2.4 Placental Biopsy
8.2.5 Cordocentesis
8.2.6 Fetal Biopsy
8.2.7 Screening Test
8.2.8 Carrier Screening
8.2.9 Sequential Screening
8.2.10 Maternal Serum Quad Screening
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hospitals
8.3.2 Clinics
8.3.3 Diagnostic Centers
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Diagnostic Test
9.2.2 Chorionic Villi Sampling (CVS)
9.2.3 Amniocentesis
9.2.4 Placental Biopsy
9.2.5 Cordocentesis
9.2.6 Fetal Biopsy
9.2.7 Screening Test
9.2.8 Carrier Screening
9.2.9 Sequential Screening
9.2.10 Maternal Serum Quad Screening
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hospitals
9.3.2 Clinics
9.3.3 Diagnostic Centers
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Sequenom Laboratories
10.1.2 Illumina
10.1.3 Natera
10.1.4 Ariosa Diagnostics
10.1.5 BGI Health
10.1.6 Natera
10.1.7 LifeCodexx
10.2 Prenatal Genetic Testing Sales Date of Major Players (2017-2020e)
10.2.1 Sequenom Laboratories
10.2.2 Illumina
10.2.3 Natera
10.2.4 Ariosa Diagnostics
10.2.5 BGI Health
10.2.6 Natera
10.2.7 LifeCodexx
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT